We are a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and immunological diseases.

Our discovery and development programs are driven by unmet medical and patient needs and strong science supported by our two patented transgenic mouse platforms(Harbour Mice®)for generating both fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb) based immune cell engager (HBICETM) bispecific antibodies. We focus on developing an innovative pipeline of Next-Gen therapeutics through our internal R&D programs, collaborations with co-discovery and co-development partners and select acquisitions.

With operations in the US, the Netherlands, and China, we also license our core platform technology to other companies and academic institutions globally.